everolimus / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

33 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
ACTRN12612000136808: Phase I study of RAD001 (Everolimus) in combination with Fluvastatin and Zoledronic acid in patients with solid tumours

Active, not recruiting
1
25
 
St George Hospital, Novartis Pharmaceuticals Australia Pty Ltd
Advanced cancers
 
 
ChiCTR-IPR-14005691: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study

Not yet recruiting
1
24
 
RT(1.5MG) ;TR(1.5mg each period)
the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution：, Shandong Xinshidai Pharmaceutical Co., Ltd.
Healthy Volunteers
 
 
ChiCTR-IPC-14005473: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study

Not yet recruiting
1
24
 
RT(1.5MG) ;TR(1.5mg each period)
the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution：, Shandong Xinshidai Pharmaceutical Co., Ltd.
Healthy Volunteers
 
 
ChiCTR-IIR-17012724: An open label, randomized, single-dose, two-period, two-sequence, crossover pivotal study to assess the bioequivalence of Everolimus Tablets 2.5mg in healthy adult subjects under fasting/ Fed condition

Recruiting
1
80
 
The first cycle of taking the test preparation on an empty stomach; the second cycle of taking the reference preparation on an empty stomach ;The first cycle of empty stomach taking reference preparation; the second cycle of empty taking the test preparation ;The first cycle after taking the test preparation; the second cycle after taking the reference preparation ;The first cycle after taking the reference preparation; the second week after taking the test preparation
The First Hospital of Jilin University; Chia Tai Tianqing Pharmaceutical Group Co, Ltd, Chia Tai Tianqing Pharmaceutical Group Co,Ltd
RCC
 
 
NCT01087554: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1
249
US
Sirolimus, Rapamune, Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Everolimus, Afinitor, Zortress, RAD001, Temsirolimus, CCI-779, Torisel
M.D. Anderson Cancer Center
Advanced Cancer
08/26
08/26
NCT01430572: Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1
62
US
Pazopanib, GW786034, Everolimus, Afinitor, RAD001
M.D. Anderson Cancer Center, GlaxoSmithKline, National Comprehensive Cancer Network
Advanced Cancers, Solid Tumors
05/20
05/20
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT02057133: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
1
198
US
LY2835219, Abemaciclib, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Eli Lilly and Company
Breast Neoplasms
03/21
12/24
NCT03154281: Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Active, not recruiting
1
24
US
niraparib, MK-4827, everolimus, Afinitor
Avera McKennan Hospital & University Health Center
Breast Cancer, Ovarian Cancer
06/23
06/24
ENCERT, NCT03328104: Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Completed
1
8
US
Everolimus, Nelarabine, Cyclophosphamide, Etoposide
Emory University
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
06/23
06/23
ChiCTR2000036064: Clinical study of PD-L1 inhibitor combined with everolimus in the treatment of refractory recurrent atypical and malignant meningiomas

Not yet recruiting
1
60
 
Everolimus 10mg PO QD ;PD-L1 inhibitor 1200mg ivgtt Q3W ;Everolimus 10mg PO QD+PD-L1 inhibitor 1200mg ivgtt Q3W
Department of neurosurgery, Beijing Tiantan Hospital, Capital Medical University; Department of neurosurgery, Beijing Tiantan Hospital, Capital Medical University, none
refractory recurrent atypical and malignant meningiomas
 
 
AZD9833, NCT04818632: China PK Study

Completed
1
28
RoW
AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus
AstraZeneca
ER+, HER2-, Metastatic Breast Cancer
09/23
09/23
NCT04135807: Implantable Microdevice In Primary Brain Tumors

Recruiting
1
12
US
Microdevice, Implantable Microdevice
Oliver Jonas, PhD
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
09/23
02/24
NCT00819546: RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Checkmark P1 data - ASH 2012
Nov 2012 - Nov 2012: P1 data - ASH 2012
Active, not recruiting
1
29
US
RAD001, everolimus, PKC412, midostaurin
Richard Stone, MD, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Novartis
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/25
12/25
NCT03740334: Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Active, not recruiting
1
45
US
Ribociclib, LEE011, Dexamethasone, Everolimus, Zortress
Dana-Farber Cancer Institute, Novartis
Acute Lymphoblastic Leukemia ALL
03/23
09/24
NCT03324373: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Active, not recruiting
1
11
US
Lenvatinib, LENVIMA®, KISPLYX®, Everolimus, AFINITOR®, Partial or Radical Cytoreductive Nephrectomy
Yousef Zakharia, Eisai Inc.
Renal Cell Carcinoma
09/23
06/28
DDU RAF/MEK, NCT02407509: Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Recruiting
1
104
Europe
VS-6766, Everolimus
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, Chugai Pharmaceutical, Verastem, Inc.
Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
05/24
05/24
TACTIVE-E, NCT05501769: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Active, not recruiting
1
32
Europe, US
ARV-471 in combination with Everolimus
Arvinas Estrogen Receptor, Inc., Pfizer
Breast Cancer
05/24
11/24
SERENA-1, NCT03616587: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Active, not recruiting
1
396
Europe, US
AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with anastrozole
AstraZeneca
ER+ HER2- Advanced Breast Cancer
07/24
09/24
NCT05189717: A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

Enrolling by invitation
1
156
RoW
HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
Shandong Suncadia Medicine Co., Ltd.
Metastatic or Local Advanced Breast Cancer of Patients
10/24
07/25
NCT05188118: Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Recruiting
1
20
US
Cabozantinib, Ipilimumab, Nivolumab, Lenvatinib, Everolimus
Icahn School of Medicine at Mount Sinai
Renal Cell Carcinoma
12/25
12/25
NCT02321501: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Active, not recruiting
1
37
US
Ceritinib, LDK 378, LDK378, Zykadia, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
12/24
12/24
NCT05293964: Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Recruiting
1
210
RoW
SIM0270, SCR6852, Palbociclib, everolimus
Jiangsu Simcere Pharmaceutical Co., Ltd.
Breast Cancer
12/24
09/25
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting
1
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
NCT05153668: Everolimus Trial in Laryngotracheal Stenosis

Active, not recruiting
1
20
US
Everolimus Oral Tablet, Zortress
Johns Hopkins University
Idiopathic Subglottic Tracheal Stenosis
03/25
03/25
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
02/25
02/25
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCI-2018-01218, NCT03065387: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Active, not recruiting
1
93
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
10/25
10/25
NCT01582191: Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASPHO 2015
Apr 2015 - Apr 2015: ASPHO 2015
Active, not recruiting
1
153
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Pharmacological Study, Vandetanib, AZD6474, Caprelsa, Zactima, ZD-6474, ZD6474
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
05/26
05/26
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27
NCT05949658: Rapalog Pharmacology (RAP PAC) Study

Recruiting
1
72
US
Sirolimus, Rapamycin, Everolimus
University of Wisconsin, Madison, National Institutes of Health (NIH), National Institute on Aging (NIA)
Aging
03/27
12/28
NCT05432518: Pilot Trial for Treatment of Recurrent Glioblastoma

Recruiting
1
10
Canada
Afatinib, Giotrif, Dasatinib, Sprycel, Palbociclib, Ibrance, Everolimus, Teva-everolimus, Olaparib, Lynparza
AHS Cancer Control Alberta, Tom Baker Cancer Centre
Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
07/27
12/27
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27

Download Options